Appointment of Marc Le Bozec as Interim CEO Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE) announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors. The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer. The Board of Directors has empowered Marc Le Bozec to lead a strategic e ...

EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced the extension of the expiration of the tender offer to purchase all outstanding shares of common shares of LAVA, for (i) a cash amount to be determined in accordance with the Purchase Agreement, plus (ii) a non-transferable contingent value right (“CVR”) per share representing the right ...

Offering was led by B Group Capital and Columbia Threadneedle Investments with significant participation from Adage Capital Partners LP, ADAR1 Capital Management, Boxer Capital Management, Coastlands Capital, Deep Track Capital, Janus Henderson Investors, Octagon Capital, Perceptive Advisors, RA Capital Management, Squadron Capital Management, and a large healthcare dedicated mutual fund Proceeds to support upcoming Phase 2 clinical development program for PALI-2108 in Ulcerative Colitis Carlsbad, CA, Oct. ...

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., has been appointed to the company’s Board of Directors. Mr. Moore brings a wealth of experience from his 27-year career in the industry, including broad expertise across strategy, commercial, market access, business development an ...

29th October 1971: City workers studying newspapers about UK entry to Europe's common market (Photo by Douglas Miller/Keystone/Getty Images)Getty ImagesIn my last article, How To Picture—And Understand—The Dow For The First Time, I showed how understanding the American stock market involves mastering the relationship between the long-term total return of leading firms and their performance on three key value-creating principles:Customer value generally outperforms short-term profitsAutonomous networks gener ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the most promising biotech stocks to buy according to hedge funds. According to a recent disclosure with the SEC, Assenagon Asset Management S.A. lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by a whopping 439.0% during the second quarter. Following the acquisition of 947,865 shares, the firm now owns 1,163,755 shares of the company’s stock, reflecting an investment worth $42,314,000 and ownership of about 1.23%. During the latest ...

CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F. Heshmatpour ...

RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it will present the positive clinical results from both its IRD gene therapy and Phentolamine Ophthalmic Solution 0.75% (POS) programs at the following medical and industry conferences in October 2025. “Thes ...

CUPERTINO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in panel discussion and host one-on-one investor meetings at the 4th Annual Roth Healthc ...

TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce today that it has received two key final reports related to i ...